# Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia

> **NCT03079505** · PHASE3 · TERMINATED · sponsor: **Hamad Medical Corporation** · enrollment: 10 (actual)

## Conditions studied

- Chronic Myeloid Leukemia - Chronic Phase

## Interventions

- **DRUG:** Dasatinib 100 MG [Sprycel]
- **DRUG:** Nilotinib 150mg oral capsule [Tasigna]

## Key facts

- **NCT ID:** NCT03079505
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-03
- **Primary completion:** 2018-09-23
- **Final completion:** 2018-09-23
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Protocol Deviation
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079505, "Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03079505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*